I sold a 15-day cash-secured put on MRNA, collecting $110 per contract expiring April 17.
This is a re-entry on MRNA after closing the previous position on April 2 for a solid gain. The setup is similar, defined risk, short duration, and a strike I’m comfortable owning at.
Why I Took It
- Short DTE (15 days) → Time decay working in my favor from day one
- $110 premium is attractive on a high-IV biotech name
- $46 strike sits below recent support — a level I’m comfortable owning
- Re-entering a ticker I know after a clean exit keeps the playbook consistent
Two Outcomes (Both Acceptable)
- Expires worthless → Keep $110 and redeploy capital
- Assigned shares → Own MRNA at $46 minus premium and begin selling covered calls
MRNA is a volatile biotech name, so position sizing is critical. The edge here isn’t predicting drug trial outcomes, it’s collecting premium in a structured, repeatable way and letting the math work over time.
Small, consistent wins. That’s the goal.
Trade Details
- 04/07/26 — Sold MRNA $46 Put (04/17) @ $110
- Premium collected: $110 per contract
- Max profit: $110 (if expires worthless)
- Breakeven: $44.90 per share
Capital is now deployed and the clock is ticking. Managing this one closely given MRNA’s tendency to move fast around any catalyst news.